Do analysts prefer MDCX or SCLX?

Medicus Pharma presently has a consensus target price of $450.00, suggesting a potential upside of 13,619.51%. Given Medicus Pharma's stronger consensus rating and higher probable upside, equities research analysts plainly believe Medicus Pharma is more favorable than Scilex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Medicus Pharma 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Scilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is MDCX or SCLX more profitable?

Medicus Pharma has a net margin of 0.00% compared to Scilex's net margin of -1,414.57%. Scilex's return on equity of 0.00% beat Medicus Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Medicus Pharma N/A -3,137.84% -263.24% Scilex -1,414.57% N/A -147.00%

Does the media favor MDCX or SCLX?

In the previous week, Medicus Pharma had 5 more articles in the media than Scilex. MarketBeat recorded 8 mentions for Medicus Pharma and 3 mentions for Scilex. Scilex's average media sentiment score of 0.36 beat Medicus Pharma's score of 0.33 indicating that Scilex is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medicus Pharma 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Scilex 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate ADXS or MDCX?

Medicus Pharma has a consensus target price of $450.00, indicating a potential upside of 13,619.51%. Given Medicus Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Medicus Pharma is more favorable than Ayala Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ayala Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Medicus Pharma 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Is ADXS or MDCX more profitable?

Ayala Pharmaceuticals' return on equity of 0.00% beat Medicus Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Ayala Pharmaceuticals N/A N/A N/A Medicus Pharma N/A -3,137.84% -263.24%

Do analysts recommend TAOX or MDCX?

Medicus Pharma has a consensus target price of $450.00, suggesting a potential upside of 13,619.51%. Given Medicus Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Medicus Pharma is more favorable than Synaptogenix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synaptogenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Medicus Pharma 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Does the media refer more to TAOX or MDCX?

In the previous week, Medicus Pharma had 5 more articles in the media than Synaptogenix. MarketBeat recorded 8 mentions for Medicus Pharma and 3 mentions for Synaptogenix. Synaptogenix's average media sentiment score of 0.37 beat Medicus Pharma's score of 0.33 indicating that Synaptogenix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Synaptogenix 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Medicus Pharma 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend MDCX or UG?

Medicus Pharma presently has a consensus price target of $450.00, suggesting a potential upside of 13,619.51%. Given Medicus Pharma's stronger consensus rating and higher probable upside, research analysts plainly believe Medicus Pharma is more favorable than United-Guardian. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Medicus Pharma 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 United-Guardian 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media favor MDCX or UG?

In the previous week, Medicus Pharma had 5 more articles in the media than United-Guardian. MarketBeat recorded 8 mentions for Medicus Pharma and 3 mentions for United-Guardian. United-Guardian's average media sentiment score of 0.94 beat Medicus Pharma's score of 0.33 indicating that United-Guardian is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medicus Pharma 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral United-Guardian 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, NNVC or MDCX?

NanoViricides is trading at a lower price-to-earnings ratio than Medicus Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NanoViricides N/A N/A -$8.29M -$0.40 N/A Medicus Pharma N/A N/A -$35.46M -$2.46 N/A

Is NNVC or MDCX more profitable?

NanoViricides' return on equity of -87.90% beat Medicus Pharma's return on equity. Company Net Margins Return on Equity Return on Assets NanoViricides N/A -87.90% -78.69% Medicus Pharma N/A -3,137.84% -263.24%

Does the media prefer NNVC or MDCX?

In the previous week, Medicus Pharma had 7 more articles in the media than NanoViricides. MarketBeat recorded 8 mentions for Medicus Pharma and 1 mentions for NanoViricides. Medicus Pharma's average media sentiment score of 0.33 beat NanoViricides' score of 0.25 indicating that Medicus Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NanoViricides 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Medicus Pharma 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Medicus Pharma (MDCX) Competitors

$3.12 -0.16 (-4.79%)

As of 01:27 PM Eastern

Compare

MDCX vs. SCLX, ADXS, TAOX, UG, and NNVC

Should you buy Medicus Pharma stock or one of its competitors? Medicus Pharma's main competitors and comparable companies include Scilex (SCLX), Ayala Pharmaceuticals (ADXS), Synaptogenix (TAOX), United-Guardian (UG), and NanoViricides (NNVC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Medicus Pharma compare to Scilex?

Medicus Pharma (NASDAQ:MDCX) and Scilex (NASDAQ:SCLX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, media sentiment, dividends and valuation.

69.7% of Scilex shares are owned by institutional investors. 8.1% of Medicus Pharma shares are owned by insiders. Comparatively, 4.5% of Scilex shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Medicus Pharma has higher earnings, but lower revenue than Scilex. Medicus Pharma is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medicus Pharma	N/A	N/A	-$35.46M	-$2.46	N/A
Scilex	$30.25M	0.81	-$358.73M	-$49.70	N/A

Medicus Pharma presently has a consensus target price of $450.00, suggesting a potential upside of 13,619.51%. Given Medicus Pharma's stronger consensus rating and higher probable upside, equities research analysts plainly believe Medicus Pharma is more favorable than Scilex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medicus Pharma	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Scilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Medicus Pharma has a beta of 0.3, suggesting that its stock price is 70% less volatile than the broader market. Comparatively, Scilex has a beta of 1.72, suggesting that its stock price is 72% more volatile than the broader market.

In the previous week, Medicus Pharma had 5 more articles in the media than Scilex. MarketBeat recorded 8 mentions for Medicus Pharma and 3 mentions for Scilex. Scilex's average media sentiment score of 0.36 beat Medicus Pharma's score of 0.33 indicating that Scilex is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medicus Pharma	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Scilex	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Medicus Pharma has a net margin of 0.00% compared to Scilex's net margin of -1,414.57%. Scilex's return on equity of 0.00% beat Medicus Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medicus Pharma	N/A	-3,137.84%	-263.24%
Scilex	-1,414.57%	N/A	-147.00%

Summary

Medicus Pharma beats Scilex on 8 of the 15 factors compared between the two stocks.

How does Medicus Pharma compare to Ayala Pharmaceuticals?

Ayala Pharmaceuticals (NASDAQ:ADXS) and Medicus Pharma (NASDAQ:MDCX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, profitability, valuation, dividends and risk.

In the previous week, Medicus Pharma had 8 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 8 mentions for Medicus Pharma and 0 mentions for Ayala Pharmaceuticals. Medicus Pharma's average media sentiment score of 0.33 beat Ayala Pharmaceuticals' score of 0.00 indicating that Medicus Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Ayala Pharmaceuticals	Neutral
Medicus Pharma	Neutral

Ayala Pharmaceuticals' return on equity of 0.00% beat Medicus Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ayala Pharmaceuticals	N/A	N/A	N/A
Medicus Pharma	N/A	-3,137.84%	-263.24%

Medicus Pharma has a consensus target price of $450.00, indicating a potential upside of 13,619.51%. Given Medicus Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Medicus Pharma is more favorable than Ayala Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ayala Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Medicus Pharma	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Ayala Pharmaceuticals has a beta of 1.75, meaning that its share price is 75% more volatile than the broader market. Comparatively, Medicus Pharma has a beta of 0.3, meaning that its share price is 70% less volatile than the broader market.

7.2% of Ayala Pharmaceuticals shares are held by institutional investors. 0.6% of Ayala Pharmaceuticals shares are held by company insiders. Comparatively, 8.1% of Medicus Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Medicus Pharma has lower revenue, but higher earnings than Ayala Pharmaceuticals. Medicus Pharma is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ayala Pharmaceuticals	$3.24M	11.05	-$48.07M	-$5.02	N/A
Medicus Pharma	N/A	N/A	-$35.46M	-$2.46	N/A

Summary

Medicus Pharma beats Ayala Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Medicus Pharma compare to Synaptogenix?

Synaptogenix (NASDAQ:TAOX) and Medicus Pharma (NASDAQ:MDCX) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends.

Synaptogenix has a beta of 1.73, indicating that its stock price is 73% more volatile than the broader market. Comparatively, Medicus Pharma has a beta of 0.3, indicating that its stock price is 70% less volatile than the broader market.

Medicus Pharma has a consensus target price of $450.00, suggesting a potential upside of 13,619.51%. Given Medicus Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Medicus Pharma is more favorable than Synaptogenix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synaptogenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Medicus Pharma	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Synaptogenix has higher revenue and earnings than Medicus Pharma. Medicus Pharma is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synaptogenix	$300K	96.29	-$28.74M	-$3.85	N/A
Medicus Pharma	N/A	N/A	-$35.46M	-$2.46	N/A

In the previous week, Medicus Pharma had 5 more articles in the media than Synaptogenix. MarketBeat recorded 8 mentions for Medicus Pharma and 3 mentions for Synaptogenix. Synaptogenix's average media sentiment score of 0.37 beat Medicus Pharma's score of 0.33 indicating that Synaptogenix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Synaptogenix	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Medicus Pharma	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Medicus Pharma has a net margin of 0.00% compared to Synaptogenix's net margin of -2,153.97%. Synaptogenix's return on equity of -128.51% beat Medicus Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Synaptogenix	-2,153.97%	-128.51%	-97.54%
Medicus Pharma	N/A	-3,137.84%	-263.24%

10.3% of Synaptogenix shares are held by institutional investors. 2.7% of Synaptogenix shares are held by insiders. Comparatively, 8.1% of Medicus Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Synaptogenix beats Medicus Pharma on 8 of the 15 factors compared between the two stocks.

How does Medicus Pharma compare to United-Guardian?

Medicus Pharma (NASDAQ:MDCX) and United-Guardian (NASDAQ:UG) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, dividends, profitability, earnings, analyst recommendations and risk.

In the previous week, Medicus Pharma had 5 more articles in the media than United-Guardian. MarketBeat recorded 8 mentions for Medicus Pharma and 3 mentions for United-Guardian. United-Guardian's average media sentiment score of 0.94 beat Medicus Pharma's score of 0.33 indicating that United-Guardian is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medicus Pharma	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
United-Guardian	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

United-Guardian has higher revenue and earnings than Medicus Pharma. Medicus Pharma is trading at a lower price-to-earnings ratio than United-Guardian, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medicus Pharma	N/A	N/A	-$35.46M	-$2.46	N/A
United-Guardian	$10.55M	2.98	$2.11M	$0.54	12.70

United-Guardian has a net margin of 22.01% compared to Medicus Pharma's net margin of 0.00%. United-Guardian's return on equity of 22.24% beat Medicus Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medicus Pharma	N/A	-3,137.84%	-263.24%
United-Guardian	22.01%	22.24%	19.12%

23.2% of United-Guardian shares are held by institutional investors. 8.1% of Medicus Pharma shares are held by insiders. Comparatively, 29.0% of United-Guardian shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Medicus Pharma has a beta of 0.3, meaning that its stock price is 70% less volatile than the broader market. Comparatively, United-Guardian has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market.

Medicus Pharma presently has a consensus price target of $450.00, suggesting a potential upside of 13,619.51%. Given Medicus Pharma's stronger consensus rating and higher probable upside, research analysts plainly believe Medicus Pharma is more favorable than United-Guardian.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medicus Pharma	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
United-Guardian	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

United-Guardian beats Medicus Pharma on 11 of the 15 factors compared between the two stocks.

How does Medicus Pharma compare to NanoViricides?

NanoViricides (NYSE:NNVC) and Medicus Pharma (NASDAQ:MDCX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, earnings and dividends.

10.3% of NanoViricides shares are held by institutional investors. 3.6% of NanoViricides shares are held by company insiders. Comparatively, 8.1% of Medicus Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

NanoViricides currently has a consensus target price of $6.00, suggesting a potential upside of 354.55%. Medicus Pharma has a consensus target price of $450.00, suggesting a potential upside of 13,619.51%. Given Medicus Pharma's higher probable upside, analysts plainly believe Medicus Pharma is more favorable than NanoViricides.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NanoViricides	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Medicus Pharma	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

NanoViricides is trading at a lower price-to-earnings ratio than Medicus Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NanoViricides	N/A	N/A	-$8.29M	-$0.40	N/A
Medicus Pharma	N/A	N/A	-$35.46M	-$2.46	N/A

In the previous week, Medicus Pharma had 7 more articles in the media than NanoViricides. MarketBeat recorded 8 mentions for Medicus Pharma and 1 mentions for NanoViricides. Medicus Pharma's average media sentiment score of 0.33 beat NanoViricides' score of 0.25 indicating that Medicus Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NanoViricides	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Medicus Pharma	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

NanoViricides' return on equity of -87.90% beat Medicus Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NanoViricides	N/A	-87.90%	-78.69%
Medicus Pharma	N/A	-3,137.84%	-263.24%

NanoViricides has a beta of 1.79, indicating that its share price is 79% more volatile than the broader market. Comparatively, Medicus Pharma has a beta of 0.3, indicating that its share price is 70% less volatile than the broader market.

Summary

NanoViricides beats Medicus Pharma on 7 of the 13 factors compared between the two stocks.

Get Medicus Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MDCX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MDCX vs. The Competition

Export

Metric	Medicus Pharma	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.91M	$12.42B	$7.27B	$12.97B
Dividend Yield	N/A	2.63%	2.51%	22.89%
P/E Ratio	-1.26	807.81	275.40	25.37
Price / Sales	N/A	748.45	562.29	78.82
Price / Cash	N/A	86.65	77.16	53.04
Price / Book	44.61	9.21	10.55	5.95
Net Income	-$35.46M	$2.84B	$3.50B	$380.75M
7 Day Performance	-61.01%	-4.00%	-3.92%	-3.96%
1 Month Performance	-60.79%	-8.07%	-8.30%	-6.81%
1 Year Performance	-97.38%	-5.86%	2.35%	-4.58%

Medicus Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MDCX Medicus Pharma	2.6217 of 5 stars	$3.12 -4.8%	$450.00 +14,309.2%	-97.2%	$3.91M	N/A	N/A	16	Gap Down
SCLX Scilex	0.3977 of 5 stars	$4.41 -0.9%	N/A	-80.5%	$37.44M	$30.25M	N/A	34	News Coverage
ADXS Ayala Pharmaceuticals	N/A	$0.60 flat	N/A	N/A	$35.79M	$3.24M	N/A	20
TAOX Synaptogenix	0.1507 of 5 stars	$4.39 -3.1%	N/A	-61.4%	$32.84M	$300K	N/A	4
UG United-Guardian	2.3081 of 5 stars	$7.10 -0.8%	N/A	-8.5%	$32.59M	$10.55M	13.15	25	Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MDCX) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Medicus Pharma (MDCX) Competitors

MDCX vs. SCLX, ADXS, TAOX, UG, and NNVC

How does Medicus Pharma compare to Scilex?

Summary

How does Medicus Pharma compare to Ayala Pharmaceuticals?

Summary

How does Medicus Pharma compare to Synaptogenix?

Summary

How does Medicus Pharma compare to United-Guardian?

Summary

How does Medicus Pharma compare to NanoViricides?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDCX vs. The Competition

Medicus Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Medicus Pharma (MDCX) Competitors

MDCX vs. SCLX, ADXS, TAOX, UG, and NNVC

How does Medicus Pharma compare to Scilex?

Do institutionals and insiders have more ownership in MDCX or SCLX?

Which has higher valuation & earnings, MDCX or SCLX?

Do analysts prefer MDCX or SCLX?

Which has more risk & volatility, MDCX or SCLX?

Does the media favor MDCX or SCLX?

Is MDCX or SCLX more profitable?

Summary

How does Medicus Pharma compare to Ayala Pharmaceuticals?

Does the media favor ADXS or MDCX?

Is ADXS or MDCX more profitable?

Do analysts rate ADXS or MDCX?

Which has more volatility and risk, ADXS or MDCX?

Do insiders and institutionals believe in ADXS or MDCX?

Which has higher valuation and earnings, ADXS or MDCX?

Summary

How does Medicus Pharma compare to Synaptogenix?

Which has more risk & volatility, TAOX or MDCX?

Do analysts recommend TAOX or MDCX?

Which has better valuation & earnings, TAOX or MDCX?

Does the media refer more to TAOX or MDCX?

Is TAOX or MDCX more profitable?

Do insiders & institutionals have more ownership in TAOX or MDCX?

Summary

How does Medicus Pharma compare to United-Guardian?

Does the media favor MDCX or UG?

Which has stronger valuation and earnings, MDCX or UG?

Is MDCX or UG more profitable?

Do institutionals and insiders hold more shares of MDCX or UG?

Which has more volatility & risk, MDCX or UG?

Do analysts recommend MDCX or UG?

Summary

How does Medicus Pharma compare to NanoViricides?

Do institutionals & insiders have more ownership in NNVC or MDCX?

Do analysts recommend NNVC or MDCX?

Which has preferable earnings & valuation, NNVC or MDCX?

Does the media prefer NNVC or MDCX?

Is NNVC or MDCX more profitable?

Which has more volatility and risk, NNVC or MDCX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDCX vs. The Competition

Medicus Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools